Product Description
AstraZeneca was developing azd-4451, an oral drug, for the treatment of bipolar disorder (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01196676)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AstraZeneca
Company Location: Europe
Company Founding Year: 1999
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Bipolar Disorder
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01196676 |
AZD4451 SAD | P1 |
Completed |
Bipolar Disorder |
2011-04-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|